HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Marketbeat reports. They currently have a $36.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 216.34% from the company’s current price.

FDMT has been the topic of a number of other research reports. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday. Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Finally, The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Stock Up 2.6%

FDMT opened at $11.38 on Monday. The firm has a 50-day moving average price of $10.39 and a 200-day moving average price of $9.51. 4D Molecular Therapeutics has a twelve month low of $4.21 and a twelve month high of $14.00. The company has a market capitalization of $594.95 million, a price-to-earnings ratio of -4.43 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. On average, sell-side analysts expect that 4D Molecular Therapeutics will post -3.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, insider David Kirn sold 15,725 shares of the firm’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $12.03, for a total value of $189,171.75. Following the completion of the transaction, the insider directly owned 884,152 shares of the company’s stock, valued at $10,636,348.56. This trade represents a 1.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 184,811 shares of company stock worth $2,075,906 in the last ninety days. 7.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC bought a new stake in 4D Molecular Therapeutics during the first quarter valued at $46,000. Millennium Management LLC increased its stake in 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of 4D Molecular Therapeutics in the 1st quarter valued at about $39,000. American Century Companies Inc. raised its holdings in shares of 4D Molecular Therapeutics by 11.5% in the 2nd quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after acquiring an additional 5,026 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after acquiring an additional 2,284 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.